Since deregulated expression of MYC through TCRA/D-MYC translocation (and also possibly through PTEN loss [12]) is a trait of this cell line, and in a recently identified NOTCH1-independent/MYC-mediated T-ALL subset [12] we evaluated the efficacy of a new, potent and selective BET/BRD4 bromodomain inhibitor, AZD5153 [39]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.